Skip to main content
. 2024 Mar 6;7(3):e241215. doi: 10.1001/jamanetworkopen.2024.1215

Figure 4. Overall Survival of Patients With Metastatic Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors (ICIs) vs Non-ICIs by Programmed Death Ligand 1 (PD-L1) Status.

Figure 4.

The diamonds indicate the pooled estimates, derived from the generic inverse variance (IV) and a random-effects model. Durva indicates durvalumab; HR, hazard ratio; and Treme, tremelimumab.